TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00743535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transobturatory correction of anterior defect plus TOT
Description: Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of mono-use needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transobturatory correction of anterior defect plus TVT
Description: Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle.
Study: NCT03417076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexagliflozin
Description: Bexagliflozin tablets, 20 mg, and bexagliflozin by IV
Study: NCT02730533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No PPI treatment
Description: No PPI treatment before ESD procedure
Study: NCT01961817

Intervention type: OTHER
Group type: OTHER
Intervention: Retromolar Vocal Cord Visualisation
Description: For easier insertion of the laryngoscope the head of the patient will be turned to the left site. Thereafter the blade (Miller) will be inserted into the mouth and pushed carefully as far as possible laterally to receive a direct view of the vocal cords. Then the performing anesthesiologist determine the Cormack \& Lehane score without and thereafter with a BURP (backward upward rightward pressure) maneuver.

Intervention type: OTHER
Group type: OTHER
Intervention: Retromolar Vocal Cord Visualisation
Description: For easier insertion of the laryngoscope the head of the patient will be turned to the left site. Thereafter the blade (Miller) will be inserted into the mouth and pushed carefully as far as possible laterally to receive a direct view of the vocal cords. Then the performing anesthesiologist determine the Cormack \& Lehane score without and thereafter with a BURP (backward upward rightward pressure) maneuver.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Vocal Cord Visualisation
Description: The head of the patient will be positioned as usual. After 2 minutes oxygen insufflation the laryngoscope will be inserted laterally to push the tongue to the left side in order to release the sight to the vocal cords. Thereafter the anesthesiologist determines the Cormack \& Lehane score without and thereafter with performance of the BURP (backward upward rightward pressure) maneuver.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Vocal Cord Visualisation
Description: The head of the patient will be positioned as usual. After 2 minutes oxygen insufflation the laryngoscope will be inserted laterally to push the tongue to the left side in order to release the sight to the vocal cords. Thereafter the anesthesiologist determines the Cormack \& Lehane score without and thereafter with performance of the BURP (backward upward rightward pressure) maneuver.
Study: NCT02448160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: alfapump
Description: Implantation of alfapump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salt-poor Human Albumin solution
Description: Patients implanted with an alfapump will receive intermittent salt-poor human albumin solution
Study: NCT01438593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercerebral implantation of allogenic CD34+ stem cell
Description: Each patient will receive brain implant of approximately 5 million allogenic Umbilical cord blood CD34+ Stem Cell
Study: NCT00830414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate
Description: IM Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medroxyprogesterone acetate
Description: IM injection
Study: NCT00840203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rowasa® 4 gm/60 mL Rectal Enema
Description: 1 x 4 gm/60 mL, single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine 4 gm/60 mL Rectal Enema
Description: 1 x 4 gm/60 mL, single-dose
Study: NCT04362293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus
Description: The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3 and low dose total body irradiation (TBI) 200 cGY on day -2 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10\^6/kg recipient weight.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
Description: The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3, plerixafor (0.24mg/Kg) subcutaneously every 12 hours on days -3 and -2 and low dose total body irradiation (TBI) 200 cGY on days -2 and -1 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10\^6/kg recipient weight.~GVHD prophylaxis will be cyclophosphamide (50mg/Kg) intravenously on days +3 and +4 and sirolimus with a loading dose 3 mg/m2 starting on day +5. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor.
Study: NCT03808376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System
Description: The Eversense® 180 CGM System
Study: NCT04268615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Covert Saccades and Virtual Reality
Description: During this intervention, patients will undergo head impulse testing while wearing virtual reality Headsets. During the head impulse tests the visual information will be modified in order to create a conflict between head rotation and rotation of the visual scene. Recording of head and eye movement will be done during these head impulses in order to verify if visual information modifies compensatory eye movements during head impulses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Covert Saccades and Virtual Reality
Description: During this intervention, patients will undergo head impulse testing while wearing virtual reality Headsets. During the head impulse tests the visual information will be modified in order to create a conflict between head rotation and rotation of the visual scene. Recording of head and eye movement will be done during these head impulses in order to verify if visual information modifies compensatory eye movements during head impulses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actives versus passives Head Impulses
Description: Patients will undergo classic passive head rotation as well as active head rotation in order to compare latencies of covert saccades in both conditions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Actives versus passives Head Impulses
Description: Patients will undergo classic passive head rotation as well as active head rotation in order to compare latencies of covert saccades in both conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visually guided saccades
Description: Patients as well as healthy control subjects will undergo testing of visually guided saccades in different conditions (step, gap, overlap) in order to compare latencies of covert saccades between both groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visually guided saccades
Description: Patients as well as healthy control subjects will undergo testing of visually guided saccades in different conditions (step, gap, overlap) in order to compare latencies of covert saccades between both groups.
Study: NCT04605211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness Meditation
Description: Complete online audio-based mindfulness meditation exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Webinars
Description: Attend webinars
Study: NCT04501848

Intervention type: PROCEDURE
Intervention: adenotonsillectomy
Description: adenotonsillectomy surgery
Study: NCT02248051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10
Description: CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
Study: NCT03333551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F18 Florbetapir (amyvid) cardiac PET/CT imaging
Description: Patients with cardiac amyloidosis (AL) undergoing planned plasma cell directed chemotherapy will have F-18 florbetapir (amyvid) cardiac PET/CT imaging prior to starting chemotherapy and six months after onset of treatment.
Study: NCT01844843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TCD-10023 drug eluting stent
Description: Implantation of new drug eluting stent in coronary artery lesions
Study: NCT01714622

Intervention type: PROCEDURE
Intervention: subtotal gastrectomy with gastroduodenostomy

Intervention type: PROCEDURE
Intervention: subtotal gastrectomy with gastroduodenostomy

Intervention type: PROCEDURE
Intervention: subtotal gastrectomy with gastroduodenostomy

Intervention type: PROCEDURE
Intervention: subtotal gastrectomy with Roux-en-Y gastrojejunostomy,

Intervention type: PROCEDURE
Intervention: subtotal gastrectomy with Roux-en-Y gastrojejunostomy,

Intervention type: PROCEDURE
Intervention: subtotal gastrectomy with Roux-en-Y gastrojejunostomy,

Intervention type: PROCEDURE
Intervention: total gastrectomy with Rou-en-Y esophagojejunostomy

Intervention type: PROCEDURE
Intervention: total gastrectomy with Rou-en-Y esophagojejunostomy

Intervention type: PROCEDURE
Intervention: total gastrectomy with Rou-en-Y esophagojejunostomy
Study: NCT01943435

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAIDs; adjunctive analgesics; adjunctive anti-depressants
Description: Physician will administer these medications based upon the individual needs of each patient.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar epidural injection
Description: The attending physician may refer subjects for epidural injections at a pain clinic that is affiliated with the University of Pittsburgh Medical Center. All epidural injections will be provided by licensed physicians who are board certified in physical medicine and rehabilitation or anesthesiology.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint Mobilizations (spine, sacroiliac, hip)
Description: These joint mobilizations will be applied manually to the lumbar facet joints, sacroiliac joints, and/or hip joints by licensed physical therapists and chiropractors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualized exercises: clinical setting
Description: The treating physical therapist or chiropractor will work with each subject to develop a set of individualized exercises in the clinic setting. The goal is to have the subjects continue these exercises at home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Exercise: community setting
Description: The group exercise will take place at community centers that provide exercise classes for older adult. The exercises are taught by certified fitness instructors in a group setting at these community centers.
Study: NCT04026048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy for Insomnia (CBT-I)
Description: CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Study: NCT03821415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP101
Description: 17β-oestradiol-3-phosphate ophthalmic sterile solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP101
Description: 17β-oestradiol-3-phosphate ophthalmic sterile solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP101
Description: 17β-oestradiol-3-phosphate ophthalmic sterile solution
Study: NCT02108535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanocrystalline silver
Description: Flexible polyester low-grip coated nano-crystalline silver layer. The level of silver is 1.64 mg/ cm². This dressing enables the sustained release of silver in humid conditions dynamically and reached a higher plateau than 60 mg / L in less than 2 hours, and maintains a uniform level by 72 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Sulfadiazine
Description: This is at Standard treatment. The cream silver sulphadiazine at 1% was applied on the burn aseptically in a thick layer, approximately 3 to 5 mm, ie 5 g per 80 cm2
Study: NCT03821415

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RP101
Description: 17β-oestradiol-3-phosphate ophthalmic sterile solution
Study: NCT01356030

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: Endoscopic retrograde cholangiopancreatography (ERCP) is usually clinically indicated to place a stent (a plastic or metal tube) in the bile duct. The ERCP procedure is an endoscopic exam during which a small catheter or wire is placed into the bile duct from the point at which it connects to the small intestine. During such a procedure a stent can then be placed to help drain the bile across the site of blockage, and thereby treat your jaundice.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS FNA
Description: Endoscopic ultrasound (EUS) is a procedure in which a flexible tube with a tiny camera and ultrasound probe at the tip is placed through the mouth, down the esophagus, and into the stomach and duodenum (first part of the small intestine where bile flows from the bile duct into the intestine). This allows the doctor performing the EUS to get a much closer view of your pancreas and bile duct. If a suspicious mass is seen, a small sample of the mass (biopsy) is taken using fine needle aspiration (FNA). FNA involves the use of a thin hollow needle to extract cells for diagnostic purposes and is considered safer and less invasive than surgical biopsies.
Study: NCT04266171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet education based on CGMS data
Description: Intervention group will receive diet education based on CGMS data, using post prandial glucose response, calculated by incremental area under curve of glucose level. Control group will receive conventional diabetes diet education without CGMS data.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional diet education
Description: Control group will receive conventional diabetes diet education without CGMS data.
Study: NCT00783120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: 10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold); in total 15.000 stimuli.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session; in total 15.000 stimuli
Study: NCT02911337

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lifestyle modification
Description: Subjects will be given meal replacements (shakes and bars) to be consumed twice per day for 8 weeks, and then once per day for an additional 3 weeks, and then transitioned to a structured diet.
Study: NCT03230864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: 10 mg/day, encapsulated tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 4-6 mg/day, encapsulated tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 4-6 mg/day, encapsulated tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 15-20 mg/day, encapsulated tablets, orally
Study: NCT01023334

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MSICS under topical anesthesia with intracameral lidocaine
Description: manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral lidocaine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MSICS under topical anesthesia with intracameral balanced salt solution.
Description: manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral balanced salt solution.
Study: NCT03230864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 15-20 mg/day, encapsulated tablets, orally
Study: NCT02524054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized saline
Description: 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized saline
Description: 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
Study: NCT01461785

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Addition of PRP ( platelet rich plasma) to the lipograft
Description: 27 ml blood will be drawn from the patient. The blood will be prepared according to the GPS System instructions (Biomet Biologics, LLC, Warsaw, Indiana USA). This desktop-size centrifuge has disposable cylinders to separate the different blood components (platelet rich plasma, PRP, platelet poor plasma, PPP, and red blood cells). The PRP is activated by adding calcium (15-volume % Ca2+ Sandoz®). creating activated Platelet Rich Plasma (aPRP).~The lipograft of Group A will be enriched with 3ml of autologous PRP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipofilling of the midface
Description: The Coleman technique for fat harvesting and injection is employed but refined by utilizing a smaller, custom-made cannula for harvesting (inner diameter, 1.3 mm). The abdomen and upper legs are donor sites. Approximately two to three times more fat is harvested than the estimated amount required for the procedure. Fat is centrifuged for three minutes at the maximum speed of 3000 revolutions per minute after which the oil layer (top) and serum/infiltrate layer (bottom) are drained away, preserving the preadipocyte-rich pellet. Fat injection is performed in 1-mm aliquots with a short, curved Coleman cannula. Between 13 and 23 mL of fat is injected into the deep subcutaneous plane of each side of the face, except for the lower lid/tear trough region (where the injection is performed in the supraperiosteal/submuscular plane) and the temporal area (where the level of injection was above the superficial fascia of the temporal muscle).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lipofilling of the midface
Description: The Coleman technique for fat harvesting and injection is employed but refined by utilizing a smaller, custom-made cannula for harvesting (inner diameter, 1.3 mm). The abdomen and upper legs are donor sites. Approximately two to three times more fat is harvested than the estimated amount required for the procedure. Fat is centrifuged for three minutes at the maximum speed of 3000 revolutions per minute after which the oil layer (top) and serum/infiltrate layer (bottom) are drained away, preserving the preadipocyte-rich pellet. Fat injection is performed in 1-mm aliquots with a short, curved Coleman cannula. Between 13 and 23 mL of fat is injected into the deep subcutaneous plane of each side of the face, except for the lower lid/tear trough region (where the injection is performed in the supraperiosteal/submuscular plane) and the temporal area (where the level of injection was above the superficial fascia of the temporal muscle).
Study: NCT00147134

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open colectomy
Description: Procedure/Surgery: open colectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic colectomy
Description: Procedure/Surgery: laparoscopic colectomy
Study: NCT01354886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSH-GEX™
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSH-GEX™
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSH-GEX™
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSH-GEX™
Description: single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f
Description: 150 IU single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bravelle
Description: 150 IU single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose
Study: NCT00845637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eggplant extract
Description: Dry eggplant extract in two 450mg capsules, twice a day (before the main meals) for fourteen days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in two 450mg capsules, twice a day (before the main meals) for fourteen days.